Sukumar Nagendran

Sukumar Nagendran has held various roles and positions in multiple companies. Sukumar currently serves as the President of Taysha Gene Therapies, where they have been since December 2022. Sukumar is also the Chair of the Compensation Committee and a member of the Audit Committee, as well as an Independent Director on the Board of Taysha Gene Therapies.

In addition to their role at Taysha Gene Therapies, Nagendran is a Board Member of Saliogen, an Independent Director of Project Healthy Minds, and a Board Member of Medocity, Inc. Sukumar also serves as a Member of the Board of Directors for both RTW Investments SPAC and Neurogene, Inc.

Nagendran has previous experience in the biotech and healthcare industries, having served as a Special Advisor for Chardan and an Advisor for Encoded Therapeutics. Sukumar has also been a Member of the Board of Directors for Solid Biosciences and held executive positions, such as President, R&D and Chief Medical Officer, at Jaguar Gene Therapy.

Overall, Sukumar Nagendran has a diverse background in multiple companies, with expertise in gene therapy and biotechnology.

Sukumar Nagendran's education history is as follows:

Sukumar Nagendran started their education in 1971 at Royal College, where they completed the Advanced Level Exam in Zoology, Chemistry, Physics, and Pure Math. In 1983, they successfully completed the 2nd MBBS exam in Anatomy, Physiology, and Biochem at North Colombo Medical College. Later, in 1988, they received a BA degree in Biochem, Psychology, and Religion from Rutgers University. Continuing their education in the medical field, Sukumar Nagendran obtained an MD degree from Rutgers Robert Wood Johnson Medical School in 1994. They further pursued their studies at Mayo Clinic Graduate School of Biomedical Sciences, where they completed a residency program in Internal Medicine from 1994 to 1997.

Throughout their career, Sukumar Nagendran continued to enhance their knowledge and skills. In 2008, they completed a program on "Strategies for Enhancing Executive Influence" at the Center for Management Research. They also acquired additional certifications, including an Executive Education for Leaders certification from The Wharton School in 2010 and a Mini MBA Program in BioPharma Innovation from Rutgers Business School in 2012.